ArticleScientific reports2021
Lung microbiome alterations in NSCLC patients.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 83 citations in OpenAlex.
- The role of the respiratory microbiome in acute and chronic respiratory diseases.Nature reviews. Microbiology · 2026Review
- M.globosa promotes lung cancer progression and M2 macrophage polarization through oxidative phosphorylation.NPJ precision oncology · 2026Article
- HIV-driven virome dysbiosis unveils distinct virome features and inter-viral correlations in blood and respiratory niches.Communications biology · 2026Article
- Defining the tumor microenvironment of non-small cell lung cancer.Immunology and cell biology · 2026Review
- Patterns of Infection and Their Impact on Survival in Lung Cancer Patients: A Retrospective Study From Saudi Arabia.Journal of epidemiology and global health · 2026Article
- Dissecting the effect of single- and co-infection of TB and COVID-19 pathogens on the sputum microbiome.Microbiology spectrum · 2026Article
- Microflora: a promising potential in the diagnosis and treatment of non-small cell lung cancer.International journal of clinical oncology · 2026Review
- From granulomas to tumors: post-tuberculosis immune and structural lung remodeling as a driver of carcinogenesis.Frontiers in immunology · 2026Review
- MARM: a framework for malignancy risk prediction from host-derived CNV in bronchoalveolar lavage fluid mNGS data with microbial admixture.Frontiers in microbiology · 2026Article
- LungMicroHostR: an R package for integrated host-microbiome analysis of bronchoalveolar lavage fluid metagenomic sequencing data.Frontiers in bioinformatics · 2026Article
- Article
- Gut-Lung Microbiota Axis Shapes the Immune Microenvironment and Immunotherapeutic Response in Lung Cancer.International journal of biological sciences · 2026Review
- Article
- Lung microbiome dynamics in health and lung cancer.Microbial genomics · 2025Review
- Ecological management of the microbiota in patients with cancer.Nature reviews. Clinical oncology · 2025Review
- Approaches for Identifying LncRNA-Associated Proteins for Therapeutic Targets and Cancer Biomarker Discovery.Targets (Basel) · 2025Article
- Review
- Dose-dependent M2 macrophage polarization induced by Talaromyces marneffei promotes lung cancer cell growth via arginine-ornithine-cycle activation.Medical microbiology and immunology · 2025Article
- Exploring the prognostic role of microbial and genetic markers in lung squamous cell carcinoma.Scientific reports · 2025Article
- One-step diagnosis of infection and lung cancer using metagenomic sequencing.Respiratory research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung is colonized by a diverse array of microbes and the lung microbiota is profoundly involved in the development of respiratory diseases. There is little knowledge about the role of lung microbiota dysbiosis in lung cancer. In this study, we performed metagenomic sequencing on bronchoalveolar lavage (BAL) from two different sampling methods in non-small cell lung cancer (NSCLC) patients and non-cancer controls. We found the obvious variation between bronchoscopy samples and lobectomy samples. Oral taxa can be found in both bronchoscopy and lobectomy samples and higher abundance of oral taxa can be found in bronchoscopy samples. Although the NSCLC patients had similar microbial communities with non-cancer controls, rare species such as Lactobacillus rossiae, Bacteroides pyogenes, Paenibacillus odorifer, Pseudomonas entomophila, Magnetospirillum gryphiswaldense, fungus Chaetomium globosum et al. showed obvious difference between NSCLC patients and non-cancer controls. Age-, gender-, and smoking-specific species and EGFR expression-related species in NSCLC patients were detected. There results implicated that different lung segments have differential lung microbiome composition. The oral taxa are found in the lobectomy samples suggesting that oral microbiota are the true members of lung microbiota, rather than contamination during bronchoscopy. Lung cancer does not obviously alter the global microbial composition, while rare species are altered more than common species. Certain microbes may be associated with lung cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.